REFERENCES
1. Virani SS, Alonso A, Aparicio HJ, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American heart association. Circulation 2021;143:e254-743.
3. Kochar A, Chen AY, Sharma PP, et al. Long-term mortality of older patients with acute myocardial infarction treated in US clinical practice. J Am Heart Assoc 2018;7:e007230.
4. Ha NT, Hendrie D, Moorin R. Impact of population ageing on the costs of hospitalisations for cardiovascular disease: a population-based data linkage study. BMC Health Serv Res 2014;14:554.
5. Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation 2019;139:e56-e528.
6. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis 2019;6:19.
7. Arnold AM, Psaty BM, Kuller LH, et al. Incidence of cardiovascular disease in older Americans: the cardiovascular health study. J Am Geriatr Soc 2005;53:211-8.
8. Dai X, Busby-Whitehead J, Alexander KP. Acute coronary syndrome in the older adults. J Geriatr Cardiol 2016;13:101-8.
9. Avezum A, Makdisse M, Spencer F, et al. GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005;149:67-73.
10. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-75.
11. Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996;27:849-53.
12. Muller-Delp JM, Spier SA, Ramsey MW, Delp MD. Aging impairs endothelium-dependent vasodilation in rat skeletal muscle arterioles. Am J Physiol Heart Circ Physiol 2002;283:H1662-72.
13. Taddei S, Virdis A, Ghiadoni L, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001;38:274-9.
14. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
15. Rush JW, Ford RJ. Nitric oxide, oxidative stress and vascular endothelium in health and hypertension. Clin Hemorheol Microcirc 2007;37:185-92.
16. van Geemen D, Soares AL, Oomen PJ, et al. Age-dependent changes in geometry, tissue composition and mechanical properties of fetal to adult cryopreserved human heart valves. PLoS One 2016;11:e0149020.
17. Westaby S, Karp RB, Blackstone EH, Bishop SP. Adult human valve dimensions and their surgical significance. Am J Cardiol 1984;53:552-6.
18. Schenk KE, Heinze G. Age-dependent changes of heart valves and heart size. Recent Adv Stud Cardiac Struct Metab 1975;10:617-24.
19. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991;68:1560-8.
20. Behar J, Yaniv Y. Age-related pacemaker deterioration is due to impaired intracellular and membrane mechanisms: insights from numerical modeling. J Gen Physiol 2017;149:935-49.
21. Fleg JL, Das DN, Wright J, Lakatta EG. Age-associated changes in the components of atrioventricular conduction in apparently healthy volunteers. J Gerontol 1990;45:M95-100.
22. Kurachi K, Kurachi S. Genetic mechanisms of age regulation of blood coagulation: factor IX model. Arterioscler Thromb Vasc Biol 2000;20:902-6.
23. Kurachi S, Deyashiki Y, Takeshita J, Kurachi K. Genetic mechanisms of age regulation of human blood coagulation factor IX. Science 1999;285:739-43.
24. Sweeney JD, Hoernig LA. Age-dependent effect on the level of factor IX. Am J Clin Pathol 1993;99:687-8.
25. Amin H, Mohsin S, Aslam M, et al. Coagulation factors and antithrombin levels in young and elderly subjects in Pakistani population. Blood Coagul Fibrinolysis 2012;23:745-50.
26. Mari D, Ogliari G, Castaldi D, Vitale G, Bollini EM, Lio D. Hemostasis and ageing. Immun Ageing 2008;5:12.
27. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505-22.
28. DelaRosa O, Pawelec G, Peralbo E, et al. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology 2006;7:471-81.
29. Wikby A, Nilsson BO, Forsey R, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev 2006;127:695-704.
30. Varadhan R, Yao W, Matteini A, et al. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. J Gerontol A Biol Sci Med Sci 2014;69:165-73.
31. Li DB, Hua Q, Liu Z, Li J, Xu LQ, Wang S, et al. Association between inflammatory mediators and angiographic morphologic features indicating thrombus formation in patients with acute myocardial infarction. Chin Med J (Engl) 2009;122:1738-42.
34. Mohebali D, Kaplan D, Carlisle M, Supiano MA, Rondina MT. Alterations in platelet function during aging: clinical correlations with thromboinflammatory disease in older adults. J Am Geriatr Soc 2014;62:529-35.
35. Nadlacki B, Horton D, Hossain S, et al. Long term survival after acute myocardial infarction in Australia and New Zealand, 2009-2015: a population cohort study. Med J Aust 2021;214:519-25.
36. Noble JM, Thomas TH, Ford GA. Effect of age on plasma membrane asymmetry and membrane fluidity in human leukocytes and platelets. J Gerontol A Biol Sci Med Sci 1999;54:M601-6.
37. Vlasic N, Medow MS, Schwarz SM, Pritchard KA, Stemerman MB. Lipid fluidity modulates platelet aggregation and agglutination. Life Sciences 1993;53:1053-60.
38. Watala C, Golański J, Boncler MA, Pietrucha T, Gwoździński K. Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 1998;9:315-27.
39. Zahavi J, Westwick J, Al-hasani S, et al. Enhanced in-vivo platelet release reaction, increased thromboxane synthesis, and decreased prostacyclin release after tourniquet ischaemia. Lancet 1980;316:663-7.
40. Bastyr EJ, Kadrofske MM, Vinik AI. Platelet activity and phosphoinositide turnover increase with advancing age. Am J Med 1990;88:601-6.
41. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003;23:2131-7.
42. Goch A, Misiewicz P, Rysz J, Banach M. The clinical manifestation of myocardial infarction in elderly patients. Clin Cardiol 2009;32:E46-51.
43. Wroblewski M, Mikulowski P, Steen B. Symptoms of myocardial infarction in old age: clinical case, retrospective and prospective studies. Age Ageing 1986;15:99-104.
44. RODSTEIN M. The characteristics of nonfatal myocardial infarction in the aged. AMA Arch Intern Med 1956;98:84-90.
45. Pathy MS. Clinical presentation of myocardial infarction in the elderly. Br Heart J 1967;29:190-9.
46. Bayer AJ, Chadha JS, Farag RR, Pathy MS. Changing presentation of myocardial infarction with increasing old age. J Am Geriatr Soc 1986;34:263-6.
47. Malik MA, Alam Khan S, Safdar S, Taseer IU. Chest Pain as a presenting complaint in patients with acute myocardial infarction (AMI). Pak J Med Sci 2013;29:565-8.
48. Ochiai ME, Lopes NH, Buzo CG, Pierri H. Atypical manifestation of myocardial ischemia in the elderly. Arq Bras Cardiol 2014;102:e31-3.
49. Rittger H, Rieber J, Breithardt OA, et al. Influence of age on pain perception in acute myocardial ischemia: a possible cause for delayed treatment in elderly patients. Int J Cardiol 2011;149:63-7.
50. Aronow WS. Prevalence of presenting symptoms of recognized acute myocardial infarction and of unrecognized healed myocardial infarction in elderly patients. Am J Cardiol 1987;60:1182.
51. Mittelmark MB, Psaty BM, Rautaharju PM, et al. Prevalence of cardiovascular diseases among older adults. The Cardiovascular Health Study. Am J Epidemiol 1993;137:311-7.
52. Jolobe OM. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J 2006;27:1383-4.
53. Melgarejo-moreno A, Galcerá-tomás J, García-alberola A, Rodríguez-garcía P, González-sánchez A. Clinical and prognostic characteristics associated with age and gender in acute myocardial infarction: a multihospital perspective in the Murcia region of Spain. Eur J Epidemiol 1999;15:621-9.
54. Solomon CG, Lee TH, Cook E, et al. Comparison of clinical presentation of acute myocardial infarction in patients older than 65 years of age to younger patients: the multicenter chest pain study experience. Am J Cardiol 1989;63:772-6.
55. Bagai A, Chen AY, Udell JA, et al. Association of cognitive impairment with treatment and outcomes in older myocardial infarction patients: a report from the NCDR Chest Pain-MI registry. J Am Heart Assoc 2019;8:e012929.
56. Leonardi S, Bueno H, Ahrens I, Hassager C, Bonnefoy E, Lettino M. Optimised care of elderly patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2018;7:287-95.
57. Han JH, Wilber ST. Altered mental status in older patients in the emergency department. Clin Geriatr Med 2013;29:101-36.
58. Auer R, Bauer DC, Marques-Vidal P, et al. Health ABC Study. Association of major and minor ECG abnormalities with coronary heart disease events. JAMA 2012;307:1497-505.
59. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the national registry of myocardial infarction. Circulation 1994;90:2103-14.
60. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999. J Am Coll Cardiol 2000;36:2056-63.
61. Hammarsten O, Fu ML, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem 2012;58:628-37.
62. Koerbin G, Tate JR, Hickman PE. Analytical characteristics of the Roche highly sensitive troponin T assay and its application to a cardio-healthy population. Ann Clin Biochem 2010;47:524-8.
63. Latini R, Masson S, Anand IS, et al. Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.
64. Arshed S, Luo HX, Zafar S, et al. Elevated troponin I in the absence of coronary artery disease: a case report with review of literature. J Clin Med Res 2015;7:820-4.
65. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:108-20.
66. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003;145:821-5.
67. Baillard C, Boussarsar M, Fosse JP, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2003;29:584-9.
68. Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016;387:1057-65.
69. Buber J, Goldenberg I, Kimron L, Guetta V. One-year outcome following coronary angiography in elderly patients with non-ST elevation myocardial infarction: real-world data from the Acute Coronary Syndromes Israeli Survey (ACSIS). Coron Artery Dis 2013;24:102-9.
70. Rajani R LM DG, et al. Evolving trends in percutaneous coronary intervention. Br J Cardiol 2011;18:73-6.
71. Kurotobi T, Sato H, Kinjo K, et al. OACIS Group. Reduced collateral circulation to the infarct-related artery in elderly patients with acute myocardial infarction. J Am Coll Cardiol 2004;44:28-34.
72. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13.
73. Damluji AA, Forman DE, van Diepen S, et al. American Heart Association Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Older adults in the cardiac intensive care unit: factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American heart association. Circulation 2020;141:e6-e32.
74. Afilalo J. Frailty in patients with cardiovascular disease: why, when, and how to measure. Curr Cardiovasc Risk Rep 2011;5:467-72.
75. Bell CM, Brener SS, Gunraj N, et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 2011;306:840-7.
76. Garpestad E, Devlin JW. Polypharmacy and delirium in critically ill older adults: recognition and prevention. Clin Geriatr Med 2017;33:189-203.
77. Tosato M, Landi F, Martone AM, et al. Investigators of the CRIME Study. Potentially inappropriate drug use among hospitalised older adults: results from the CRIME study. Age Ageing 2014;43:767-73.
78. Mittel A, Hua M. Supporting the geriatric critical care patient: decision making, understanding outcomes, and the role of palliative care. Anesthesiol Clin 2019;37:537-46.
79. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol Pol 2018;76:229-313.
80. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004;61:498-511.
81. Li S, Tarlac V, Hamilton JR. Using PAR4 inhibition as an anti-thrombotic approach: why, how, and when? Int J Mol Sci 2019;20:5629.
82. Ornelas A, Zacharias-Millward N, Menter DG, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 2017;36:289-303.
83. Wickramarachchi U, Ho HH, Eccleshall S. Drug-coated balloons in STEMI. In: Watson TJ, Ong PJL, Tcheng JE, editors. Primary Angioplasty: a Practical Guide. Singapore 2018. p. 151-65.
84. Goldstein RE, Andrews M, Hall WJ, Moss AJ. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996;28:326-30.
85. Aronow WS, Ahn C. Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins. Heart Dis 2002;4:159-61.
86. Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66.
87. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
88. Husted S, James S, Becker RC, et al. PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;5:680-8.
89. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 2014;35:2083-93.
90. Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation 2020;142:1700-8.
91. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009;7:1195-201.
92. Cavender MA, Bhatt DL, Stone GW, et al. CHAMPION PHOENIX Investigators*. Cangrelor in older patients undergoing percutaneous coronary intervention: findings from CHAMPION PHOENIX. Circ Cardiovasc Interv 2017;10:e005257.
93. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
94. Savonitto S, Ferri LA, Piatti L, et al. Elderly ACS 2 Investigators. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation 2018;137:2435-45.
95. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549-58.
96. Guagliumi G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004;110:1598-604.
97. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;64:e139-228.
98. Steg PG, Jolly SS, Mehta SR, et al. FUTURA/OASIS-8 Trial Group. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010;304:1339-49.
99. a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990;336:65-71.
100. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e24S-43S.
101. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011;378:693-703.
102. Puymirat E, Aïssaoui N, Collet JP, et al. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. Int J Cardiol 2013;166:106-10.
103. Claessen BE, Guedeney P, Gibson CM, et al. Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc 2020;9:e018897.
104. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008;51:37-45.
105. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Kardiol Pol 2016;74:1234-318.
106. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-70.
107. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
108. Mitchell S, Roso S, Samuel M, Pladevall-Vila M. Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord 2016;16:74.
109. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-8.
110. effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
111. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
112. Gianni M, Bosch J, Pogue J, et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J 2007;28:1382-8.
113. trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
114. intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32.
115. Norris R, Brown M, Clarke E, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984;324:883-6.
116. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422-37.
117. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-8.
118. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:E1-E211.
119. Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. Cardiovasc Drugs Ther 2016;30:367-78.
120. Miller MR, Wadsworth RM. Understanding organic nitrates--a vein hope? Br J Pharmacol 2009;157:565-7.
121. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. Lancet 1994;344(8915):91-7.
122. a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.
123. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). G Ital Cardiol (Rome) 2016;17:831-72.
124. Newell MC, Henry JT, Henry TD, et al. Impact of age on treatment and outcomes in ST-elevation myocardial infarction. Am Heart J 2011;161:664-72.
125. Bueno H, Betriu A, Heras M, et al. TRIANA Investigators. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J 2011;32:51-60.
126. Kaura A, Sterne JAC, Trickey A, et al. Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. Lancet 2020;396:623-34.
127. Shanmugasundaram M. Percutaneous coronary intervention in elderly patients: is it beneficial? Tex Heart Inst J 2011;38:398-403.
128. Damman P, Clayton T, Wallentin L, et al. Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials. Heart 2012;98:207-13.
129. McCullough PA, Gibson CM, Dibattiste PM, et al. TACTICS-TIMI-18 Investigators. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol 2004;17:81-6.
130. Gnanenthiran SR, Kritharides L, D'Souza M, Lowe HC, Brieger DB. Revascularisation compared with initial medical therapy for non-ST-elevation acute coronary syndromes in the elderly: a meta-analysis. Heart 2017;103:1962-9.
131. CDC. Interactive Atlas of Heart Disease and Stroke 2019. Available from: https://nccd.cdc.gov/DHDSPAtlas/Reports.aspx [Last accessed on 9 Aug 2022].
